Bicara Therapeutics(BCAX)

BOSTON, MA

Biotechnology

Focus: Dual-Action Biologics, Antibodies

Bicara Therapeutics is a life sciences company focused on Dual-Action Biologics, Antibodies.

OncologyUnknown

Funding Stage

PUBLIC

Open Jobs

Pipeline & Clinical Trials

BCA101

Phase 1

Ficerafusp alfa

Phase 2/3

Clinical Trials (1)

NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Phase 2/3

Interview Prep Quick Facts

Founded: 1997

Portfolio: 1 clinical trial

SEC Filings: 1 available

Open Roles: 1 active job

R&D Spend

$31M

Net Income

-$52M

Cash

$230M